(Q37132850)

18 August 2017

1 reference

title

BCR/ABL, DNA damage and DNA repair: implications for new treatment concepts (English)

1 reference

18 August 2017

0 references

1

Tomasz Skorski

1 reference

18 August 2017

1 April 2008

1 reference

18 August 2017

1 reference

18 August 2017

49

1 reference

18 August 2017

4

1 reference

18 August 2017

610-614

1 reference

Fusion tyrosine kinases: a result and cause of genomic instability

18 August 2017

1 reference

https://api.crossref.org/works/10.1080%2F03093640701859089

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03093640701859089

The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03093640701859089

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03093640701859089

Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03093640701859089

Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03093640701859089

The CNS is a sanctuary for leukemic cells in mice receiving imatinib mesylate for Bcr/Abl-induced leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03093640701859089

Leukemia stem cells in a genetically defined murine model of blast-crisis CML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03093640701859089

Clinical and pathologic analysis of 16 cases of relapsed chronic myeloid leukemia after stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03093640701859089

Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03093640701859089

High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03093640701859089

Instability of BCR-ABL gene in primary and cultured chronic myeloid leukemia stem cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03093640701859089

Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03093640701859089

Loss of p53 impedes the antileukemic response to BCR-ABL inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03093640701859089

BCR/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03093640701859089

p210 BCR/ABL kinase regulates nucleotide excision repair (NER) and resistance to UV radiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03093640701859089

BCR/ABL modifies the kinetics and fidelity of DNA double-strand breaks repair in hematopoietic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03093640701859089

The interacting pathways for prevention and repair of oxidative DNA damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03093640701859089

Mutator phenotype of BCR--ABL transfected Ba/F3 cell lines and its association with enhanced expression of DNA polymerase beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03093640701859089

ATR-Chk1 axis protects BCR/ABL leukemia cells from the lethal effect of DNA double-strand breaks.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03093640701859089

Rad51 overexpression promotes alternative double-strand break repair pathways and genome instability

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03093640701859089

BCR/ABL regulates mammalian RecA homologs, resulting in drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03093640701859089

Chronic myeloid leukaemia: stem cell derived but progenitor cell driven

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03093640701859089

Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03093640701859089

Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03093640701859089

Punish the parent not the progeny.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03093640701859089

Primitive, quiescent and difficult to kill: the role of non-proliferating stem cells in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03093640701859089

Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03093640701859089

Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03093640701859089

Why do chronic myelogenous leukemia stem cells survive allogeneic stem cell transplantation or imatinib: does it really matter?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03093640701859089

Characterization of cancer stem cells in chronic myeloid leukaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03093640701859089

10.1080/03093640701859089

21 January 2018

Identifiers

DOI

1 reference

18 August 2017

1 reference

PubMed ID

18398719